Back to UBS Group AG UBS Group AG

EFTREFTR
12 quarters

Position history for UBS Group AGUBS Group AG's holdings in eFFECTOR Therapeutics, Inc.

UBS Group AG previously held 0 shares of EFTR (eFFECTOR Therapeutics, Inc.), worth $0 as of 2024-Q3.

Final Value

$0

Final Shares

0

Total Value Change

-$20,000

Total Shares Change

-2,401

Quarter-by-Quarter History
QuarterActionSharesChangeValueWeightPriceConviction
2024-Q3
Latest
Exited
0
-100.0%
$00.0%$0.04
0
2024-Q2
New
61,667
-
$17,8830.0%$0.29
28
2024-Q1
Exited
0
-100.0%
$00.0%$14.39
0
2023-Q4
Decreased
9,092
-7.9%
$4,2460.0%$11.69
0
2023-Q3
New
9,874
-
$5,9240.0%$15.00
24
2023-Q2
Exited
0
-100.0%
$00.0%$18.99
0
2023-Q1
Decreased
21,414
-18.5%
$7,5590.0%$8.74
0
2022-Q4
Increased
26,263
+58.6%
$11,2930.0%$10.69
17
2022-Q3
New
16,558
-
$9,0000.0%$14.25
26
2022-Q2
Exited
0
-100.0%
$00.0%$36.75
0
2022-Q1
Decreased
141
-94.1%
$1,0000.0%$101.25
0
2021-Q4
New
2,401
-
$20,0000.0%$194.25
29

Other major holders of EFTR: Blackstone Inc., Carlyle Group Inc.

Analytics tracking helps us improve the product. Essential functions stay on either way. How analytics data is used